Skip to main content
TipRanks
Go Ultimate75% OFF

Gongwin Biopharm Holdings Co., Ltd. (6617) AI Stock Analysis

TW:6617

Gongwin Biopharm Holdings Co., Ltd.

(TPEx:6617)

Select Model
Rating:44Neutral
Price Target:TWD 121.00â–¼(-3.20% Downside)
Action:upgraded
Date:11/18/26

The overall score is severely depressed by the company's dire financial state, marked by collapsing revenues and massive cash burn. While the stock shows some positive technical momentum, the fundamental business is in crisis. The negative P/E ratio further confirms a lack of earnings power, making the stock a high-risk proposition.

Positive Factors
Long-term Revenue ExpansionThe substantial multi-year increase in revenue indicates that Gongwin has expanded its commercial activity and potential market reach. Although the latest year was slightly weaker, the longer growth trajectory provides a foundation for future operating leverage if the company can convert scale into improved profitability.
Negative Factors
Severe Operating LossesExtremely large operating losses relative to revenue show that the current cost structure is not yet compatible with a sustainable earnings model. This weakens the quality of revenue growth, increases dependence on continued funding, and makes a durable path to profitability highly uncertain over the next several quarters.

Gongwin Biopharm Holdings Co., Ltd. (6617) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%80%TW:6617+56.84%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 15.02B
Dividend Yield
―
Average Volume (3M)
866.74K
Price to Earnings (P/E)
-103.7
Beta (1Y)
0.99
Revenue Growth
11.66%
EPS Growth
-72.96%
Country
TW
Employees
20
Sector
General
Sector Strength
55
Industry
Medical - Distribution

Gongwin Biopharm Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concl...

Gongwin Biopharm Holdings Co., Ltd. Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows a -92.8% revenue collapse and a -358.8% net margin. Cash flow is deeply negative with a -$188.9M free cash flow, and the balance sheet equity is eroding rapidly. The only minor positive is low debt, but it is insufficient to offset the severe operational distress.

Income Statement

8Very Negative

Balance Sheet

45Neutral

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Mar 2023Dec 2021
Income Statement
Total Revenue41.83M36.45M32.04M18.91M1.14M1.14M
Gross Profit9.41M14.99M8.68M11.20M1.07M1.08M
EBITDA-280.24M-196.19M-75.97M-81.05M-275.56M-100.58M
Net Income-150.10M-114.13M-82.55M-92.04M-254.19M-121.58M
Balance Sheet
Total Assets2.58B2.80B3.38B1.52B1.62B1.17B
Cash, Cash Equivalents and Short-Term Investments1.65B1.82B2.39B1.08B1.32B909.82M
Total Debt150.78M129.74M126.75M77.17M141.74M115.14M
Total Liabilities310.54M279.20M281.84M203.53M248.70M184.43M
Stockholders Equity2.28B2.53B3.11B1.32B1.39B970.72M
Cash Flow
Free Cash Flow-188.87M-138.21M-293.54M-111.93M-238.37M-95.56M
Operating Cash Flow-186.41M-135.75M-87.41M-110.80M-232.20M-95.51M
Investing Cash Flow-322.69M600.68M-1.20B-280.97M-202.00M-246.42M
Financing Cash Flow-88.47M-388.61M1.88B-12.10M604.05M101.77M

Gongwin Biopharm Holdings Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price125.00

Price Trends

50DMA123.71Positive
100DMA109.16Positive
200DMA90.06Positive

Market Momentum

MACD1.32Negative
RSI57.06Neutral
STOCH89.19Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:6617, the sentiment is Positive. The current price of 125.00 is above the 20-day moving average (MA) of 115.80, above the 50-day MA of 123.71, and above the 200-day MA of 90.06, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 57.06 is Neutral, neither overbought nor oversold. The STOCH value of 89.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TW:6617.

Gongwin Biopharm Holdings Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6617 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:1720TW:172073OutperformTWD 10.87B10.84―3.62%4.62%9.56%
TW:4114TW:411461NeutralTWD 14.35B17.11―3.18%20.99%5.70%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6617TW:661744NeutralTWD 16.26B-103.66――11.66%-72.96%
TW:6576TW:657642NeutralTWD 11.26B510.71――6.41%―

* General Sector Average

Performance Comparison

0%50%TW:6617TW:1720TW:4114TW:6467TW:6576TW:6589Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6617 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6617Gongwin Biopharm Holdings Co., Ltd.125.0047.3060.88%
TW:1720Standard Chemical & Pharmaceutical Co. Ltd.55.10-0.28-0.51%
TW:4114Synmosa Biopharma Corp26.55-1.92-6.75%
TW:6467TAHO Pharmaceuticals Ltd231.0061.0035.88%
TW:6576Foresee Pharmaceuticals Co., Ltd.70.60-5.10-6.74%
TW:6589EirGenix, Inc.53.00-19.80-27.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026